Eos

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Concinnity Genetics transforms the safety of gene therapies by designing novel control mechanisms using an AI platform.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Naturbeads Ltd, established in 2018 and located in Malmesbury, United Kingdom, specializes in producing biodegradable cellulose microparticles designed to replace plastic microbeads commonly found in cosmetics, toiletries, and various industrial applications such as paints and adhesives. The company's innovative technology, developed at the University of Bath, offers an eco-friendly alternative that aims to mitigate the environmental impact of microplastic pollution in oceans and soil. By substituting fossil-fuel-based plastic with natural cellulose beads, Naturbeads enables its customers to adopt more sustainable practices and contribute to reducing pollution associated with conventional microbeads.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments.

Neupulse, a brand of Neurotherapeutics Ltd, focuses on developing non-drug treatments for individuals with tic disorders, particularly Tourette Syndrome. The company has designed a wearable device that utilizes rhythmic peripheral nerve stimulation to help users monitor and gain control over their tics. Feedback from individuals with tic disorders and their families guided Neupulse’s research priorities, emphasizing the need for safe and effective treatments that can be used outside clinical settings. Their innovative approach involves delivering mild electrical stimulation to the median nerve at the wrist, which has been shown to enhance brain oscillations associated with the suppression of tics. This method not only significantly reduces the frequency of tics and the urge to tic but also maintains the ability to perform voluntary movements and cognitive functions.

Wobble Genomics is a biotechnology firm focused on enhancing the efficiency of RNA and DNA sequencing to facilitate the discovery and detection of nucleic acid biomarkers. The company employs a blend of biochemistry and bioinformatics to achieve unprecedented sensitivity and accuracy in identifying novel biomarkers. By optimizing sampling efficiency during sequencing, Wobble Genomics aims to reduce costs for medical researchers, thereby advancing the field of genomic analysis and improving diagnostic capabilities.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

Chemify is a developer of a chemical digitization platform that integrates automated synthetic hardware with a unique chemical programming language. This platform allows for the on-demand conversion of digital code into molecules, facilitating drug and materials discovery as well as chemical synthesis. Chemify's system is designed to be modular, universal, scalable, and teachable, making it suitable for various applications in chemical and material research. The software incorporates natural language processing to translate synthetic procedures and features a comprehensive ontology, which aids users in creating chemical processes while providing insights into reaction conditions and identifying potential issues. This capability enables scientists to access detailed real-time telemetry of chemical reactions, enhancing efficiency and accuracy in their work.

Bioliberty is a medtech start-up focused on creating innovative rehabilitation solutions for individuals with degenerative and traumatic conditions. The company develops robotic gloves that leverage artificial intelligence to facilitate muscle recovery. By utilizing assistive robotics and rehabilitative devices, Bioliberty aims to support patients suffering from various ailments, including stroke, motor neuron disease, multiple sclerosis, rheumatoid arthritis, and osteoarthritis. These devices are designed to assist users in overcoming hand weakness, enabling them to perform daily tasks more effectively and enhance their hand strength, ultimately promoting greater independence and comfort in their own homes.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Waire Health specializes in the development of wearable vital sign monitoring devices aimed at identifying high-risk patients in hospital wards and at home. By employing advanced artificial intelligence, the company's technology continuously monitors vital signs to detect patterns that may indicate the onset of conditions such as sepsis. This proactive monitoring allows clinicians to receive timely information, facilitating early intervention and improving patient outcomes. By operating autonomously, Waire's solutions help reduce healthcare costs while enhancing the quality of care for patients.

Green Bioactives is a company focused on sustainable biomanufacturing, specializing in the production of plant biomolecules through a cell-based platform. This innovative approach involves identifying, isolating, and cultivating plant vascular stem cells, allowing for the development of bioactive molecules suitable for various commercial applications. The company's technology aims to provide new solutions for the cosmetic, pharmaceutical, food, and agricultural sectors, addressing the global demand for efficient and sustainable food production. By leveraging natural plant biochemistry, Green Bioactives offers a reliable and economical alternative to traditional methods, promoting sustainability in multiple industries.

Penrhos Bio develops a bioscience platform designed to address challenges posed by bacterial and microbial biofilms in various sectors, including consumer, healthcare, and industrial environments. The company creates novel, organically inspired substances that serve as sustainable, low-toxicity alternatives to traditional biocides, effectively targeting bacterial communication and quorum sensing through multiple mechanisms. This innovative approach provides solutions to microbial contamination issues across industries such as marine, textile, paper, household cleaning, and medical sectors.

RAB Microfluidics specializes in diagnosing early signs of failure in lubricated machinery, such as gearboxes in wind turbines and engines in the mining industry, using its patented microfluidic technology and artificial intelligence. The company has automated the lubricating oil analysis process, enabling real-time delivery of critical data that identifies equipment deterioration and potential failures. This innovation aims to revolutionize maintenance practices by enhancing equipment reliability and availability through early diagnosis. RAB Microfluidics targets various industries, including maritime, renewable energy, aerospace, and manufacturing, with the goal of facilitating a transition to condition-based and predictive maintenance strategies. By providing intelligent insights and data-driven automation solutions, RAB Microfluidics seeks to improve asset condition management while significantly reducing costs.

Naturbeads Ltd, established in 2018 and located in Malmesbury, United Kingdom, specializes in producing biodegradable cellulose microparticles designed to replace plastic microbeads commonly found in cosmetics, toiletries, and various industrial applications such as paints and adhesives. The company's innovative technology, developed at the University of Bath, offers an eco-friendly alternative that aims to mitigate the environmental impact of microplastic pollution in oceans and soil. By substituting fossil-fuel-based plastic with natural cellulose beads, Naturbeads enables its customers to adopt more sustainable practices and contribute to reducing pollution associated with conventional microbeads.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

Wobble Genomics is a biotechnology firm focused on enhancing the efficiency of RNA and DNA sequencing to facilitate the discovery and detection of nucleic acid biomarkers. The company employs a blend of biochemistry and bioinformatics to achieve unprecedented sensitivity and accuracy in identifying novel biomarkers. By optimizing sampling efficiency during sequencing, Wobble Genomics aims to reduce costs for medical researchers, thereby advancing the field of genomic analysis and improving diagnostic capabilities.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

RAB Microfluidics specializes in diagnosing early signs of failure in lubricated machinery, such as gearboxes in wind turbines and engines in the mining industry, using its patented microfluidic technology and artificial intelligence. The company has automated the lubricating oil analysis process, enabling real-time delivery of critical data that identifies equipment deterioration and potential failures. This innovation aims to revolutionize maintenance practices by enhancing equipment reliability and availability through early diagnosis. RAB Microfluidics targets various industries, including maritime, renewable energy, aerospace, and manufacturing, with the goal of facilitating a transition to condition-based and predictive maintenance strategies. By providing intelligent insights and data-driven automation solutions, RAB Microfluidics seeks to improve asset condition management while significantly reducing costs.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

GM Flow specializes in providing flow measurement services and products tailored for the oil and gas industry. The company develops advanced gas flow measurement equipment that includes features such as data logging capabilities, battery power, and wireless options. These innovations enable operators to accurately measure flow and pressure rates in challenging oilfield environments, ensuring safety and precision in their operations. GM Flow's commitment to enhancing energy measurement services positions it as a key player in supporting the efficiency and reliability of oil and gas operations.

Rooser is a business-to-business platform based in Edinburgh, Scotland, that facilitates seafood trade across Europe. The company provides a cloud-based marketplace specifically for fresh fish, allowing seafood buyers and suppliers to connect and engage in efficient commerce. Rooser's platform simplifies the trading process by enabling users to negotiate prices and manage deliveries effectively, thus enhancing the overall efficiency of seafood transactions in the market.